Gastrointestinal Cancer News

The prevalence of colorectal cancer and advanced colorectal neoplasia is not insignificant among patients with a positive fecal immunochemical test result who have undergone recent colonoscopies, according to research published in Gastrointestinal Endoscopy.

Eureka Therapeutics announced that the FDA has cleared its investigational new drug application for ET140202 ARTEMIS T-cell therapy for patients with hepatocellular carcinoma who are positive for alpha-fetoprotein, according to a press release.

Pembrolizumab induced durable antitumor activity among patients with advanced, metastatic esophageal cancer whose disease progressed after two or more lines of treatment, according to results of the open-label, phase 2 KEYNOTE-180 study published in JAMA Oncology.

Fecal immunochemical tests have lower positive predictive value of colorectal cancer among patients who are regular users of aspirin and direct-acting oral anticoagulants, according to research published in Gastroenterology.

A test that captures genetic biomarkers from the esophagus using a small sponge can help identify signs of Barrett’s esophagus leading to the early detection of esophageal cancer, according to research published in Clinical Cancer Research.

The Dana-Farber Cancer Institute has received up to $25 million to begin a project that will aim to discover how certain microbes inside a person’s body lead to colorectal cancer and influence a patient’s response to treatment, according to a press release.

Patients who underwent liver transplantation demonstrated an increased trend toward developing colon cancer and non-Hodgkin lymphoma, according to a press release and data presented at this year’s American College of Gastroenterology Annual Scientific Meeting.

Stereotactic body radiation therapy showed promising rates of local control and survival in patients diagnosed with early-stage hepatocellular carcinoma, according to a North American pooled analysis presented at ASCO Gastrointestinal Cancers Symposium.

FDA granted clearance to 23andMe’s genetic health risk report for MUTYH-associated polyposis, a hereditary colorectal cancer syndrome.

Patients with complete response to hepatocellular carcinoma and underwent direct-acting antiviral therapy for hepatitis C had similar rates of cancer recurrence compared with patients who did not receive DAA therapy, according to a study published in Gastroenterology.